CCM
XLRN

Chiron Capital Management’s Acceleron Pharma XLRN Stock Holding History

Chiron Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-745
Closed -$84K – 501
2020
Q3 		$84K Buy
+745
New +$74.2K 0.07% 119

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Chiron Capital Management's XLRN Position: Q4 2020 in Review

Chiron Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 745 shares — an estimated $84K sold.

Chiron Capital Management first reported a position in XLRN in Q3 2020 and held it in 1 quarter. The position peaked at $84K in Q3 2020. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

  • Chiron Capital Management reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 745 Acceleron Pharma shares in Q4 2020, an estimated $84K.
  • Chiron Capital Management first reported a position in Acceleron Pharma in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's Acceleron Pharma position peaked at $84K in Q3 2020.
  • 253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.